Why Should Hydrocodone Combination Products Be Categorized as CII Drugs?

Published Online: Thursday, January 30, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, explains why hydrocodone combination products should no longer be categorized as Schedule III drugs.
 
This is the eleventh in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
I distinctly remember feeling surprised when the FDA approved the first single entity and extended-release hydrocodone pain medication.
Ludy L. Underwood, Cardinal Health sales manager for retail/alternative care, pharmaceutical division, talks about how health information technology has changed the business of pharmacy.
Ludy L. Underwood, Cardinal Health sales manager for retail/alternative care, pharmaceutical division, talks about how Cardinal Health has helped pharmacies reduce costs.
Ludy L. Underwood, Cardinal Health sales manager for retail/alternative care, pharmaceutical division, talks about how Cardinal Health’s Generation Rx program raises awareness of prescription drug abuse.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$